All 1 tracked stories fall under one category: market-trends. Amprius Technologies is most often covered alongside Cibotercept, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Amprius Technologies
All 1 tracked stories fall under one category: market-trends. Amprius Technologies is most often covered alongside Cibotercept, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Healthcare story that mention Amprius Technologies, all published on March 4, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Amprius Technologies. Shared-story counts are live from our verified record — not editorial picks.
Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.